Underweight — Trim 25-50% on bounces toward $64-65; Stop at $58.02
Underweight is the correct synthesis rating that honors the 9/16 reflection's directive for partial trim in floor-consensus setups while respecting the 9/10 reflection's constraint capping trim at 40-50%. The rating sizes the underweight to the floor the balance sheet provides, not to the bearish conviction, and preserves asymmetric optionality ahead of Q3 earnings and CYTK ruling. The trader's SELL action is directionally supported but should be executed as a measured 25-50% trim on bounces, not as full liquidation. Capital preservation with defined re-engagement triggers outperforms both forced selling at breakdown and passive carry through alpha leak.
| Position | Action |
|---|---|
| Relief bounce toward $64-65 (10 EMA at $64.32 / 50 SMA at $63.91 cluster) | Trim 25-50% of existing BMY exposure — first tranche at $64, second tranche at $65 |
| Post-trim residual | Maintain 1.0-1.5% portfolio weight for 3.95% dividend carry and 0.227-beta structural floor |
| No new initiations | Forward PE of 9.57x optically attractive but entry risk-reward does not justify new capital deployment |
| Any future re-engagement | Cap at 2% portfolio weight maximum |
BMY is a defensive mega-cap pharma in the early innings of an earnings inflection, trading at a 9.6x forward P/E with a first-in-class CAR-T catalyst the market is just beginning to digest.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | 64.32 | bearish |
| 50 SMA | 63.91 | bearish |
| 200 SMA | 58.02 | bullish |
| RSI(14) | 39.33 | bearish |
| MACD | -0.24 | bearish |
| MACD Histogram | -0.58 | bearish |
| MACD Signal | +0.34 | neutral |
| Bollinger Middle (20 SMA) | 65.79 | neutral |
| Bollinger Lower Band | 62.29 | bullish |
| ATR(14) | 1.45 | neutral |
Support: 62.29 · 62.52 · 58.02 | Resistance: 63.91 · 64.32 · 65.79 · 68.09
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Successful reclaim of 50 SMA ($63.91) with MACD histogram contracting negative AND RSI reclaiming 45+
Then: Add 25% of intended size
↩ rebuts: “Patent cliff on Eliquis/Revlimid/Opdivo”
BMY is a stock built on accounting optics, pipeline hype, and 45% intangible assets that is structurally over-leveraged with negative tangible book value, a dividend only covered by normalized FCF at 1.16x, and technical breakdown suggesting the path of least resistance is lower.
· concedes: First-in-class doesn't equal commercial success (acknowledges KarXT/Cobenfy is 'genuinely novel'); Q2 2026 EPS of $1.62 is technically a recovery (but from depressed base, not structural step-change); D/E ratio is technically improving (but still 2.0x with negative tangible book); Healthcare sector is outperforming (but BMY specifically is lagging); Arlo-cel did hit its Phase 2 primary endpoint (but addressable population is small fraction of multiple myeloma market); FCF TTM aggregate does cover the dividend (but only due to one outlier quarter)
→ vs conservative: The 'hold and collect the dividend' strategy is negligence dressed as prudence; dividend coverage at 1.16x is razor-thin and one impairment event away from triggering a dividend review or cut, not a fortress
→ vs neutral: The 'wait for confirmation' mentality is procrastination; all confirmation signals are already present (close below lower Bollinger Band, bearish MACD crossover with expanding histogram, breakdown below 50 SMA), and waiting only results in entering at a worse price with the same risk profile
→ vs neutral: Framing arlo-cel Phase 2 data as 'thesis-altering' is narrative hopium that ignores the math on a 17.7 PEG and the scale of revenue replacement needed for Eliquis and Revlimid
BMY printed a near-term peak at 68.09 on Sep 3 and has since pulled back for 10+ sessions, breaking below the 10 EMA (64.32) and 50 SMA (63.91). Momentum is decisively bearish across all three measures: RSI at 39.33 shows bearish divergence from the Aug 19 peak (69.0), MACD crossed below its signal line on Sep 15, and the histogram is expanding negative (-0.34 to -0.58 since Sep 8). Price is testing the lower Bollinger Band at 62.29; a sustained close below this level targets the $60 psychological zone and the 200 SMA at 58.02. Bulls must reclaim 63.91/50 SMA to invalidate the bearish MACD crossover and reopen the path to 65.79 and 68.09.
Market Cap
$128.4 billion
PE Ratio (TTM)
13.84x
Forward PE
9.57x
PEG Ratio
17.71
Price/Book
5.75x
EPS (TTM)
$4.54
Forward EPS
$6.56
Dividend Yield
3.96%
Beta
0.227
52-Week Range
$42.52 - $68.64
Revenue (TTM)
$49.19B
Gross Margin
71.7%
Operating Margin (TTM)
34.4%
Net Profit Margin
18.9%
ROE
46.6%
ROA
10.7%
Current Ratio
1.53
Debt/Equity
201.9%
Total Debt
$45.05B
Net Debt
$34.40B
Total Assets
$87.63B
Total Liabilities
$65.32B
Stockholders' Equity
$22.32B
Cash & Equivalents
$8.72B
Goodwill
$21.74B
Other Intangibles
$17.63B
Working Capital
$9.92B
FCF (TTM)
$8.11B
OCF Q2 2026
$3.39B
Dividend Coverage
~1.6x FCF/Div
Q2 2026 EPS
$1.62
Forward EPS Growth
+44%
Annual Dividend
$2.52/share
R&D Investment Q2 2026
$2.96B
Interest Expense
~$1.9B annually
Tangible Book Value
-$17.0B
Strengths
Concerns
Bristol-Myers Squibb demonstrates a compelling fundamental turnaround with Q2 2026 EPS of $1.62 representing significant expansion from the ~$0.85 quarterly average, while the 3.96% dividend yield and $8.11B TTM FCF support income and deleveraging objectives. The attractive forward PE of 9.6x versus TTM 13.8x suggests double-digit earnings growth as recently acquired assets (KarXT, Mirati, RayzeBio) ramp up. However, the stock trades near its 52-week high with elevated Debt/Equity of 201.9%, $39.4B in goodwill/intangibles, and meaningful LOE risk on $20B+ blockbuster franchise, warranting a HOLD stance pending pullback to the $58-60 zone for better risk/reward.